HBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Harvard Bioscience's Forward PE Ratio for today is 0.00.
Harvard Bioscience's PE Ratio without NRI for today is 144.80.
Harvard Bioscience's PE Ratio for today is 0.00.
The historical data trend for Harvard Bioscience's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Bioscience Annual Data | |||||||||||||||||
Trend | 2015-12 | 2016-12 | 2017-12 | 2018-12 | 2019-12 | 2020-12 | 2021-12 | 2022-03 | |||||||||
Forward PE Ratio | 18.25 | 16.05 | 18.87 | 11.43 | 14.27 | 14.79 | 19.57 | 15.06 |
Harvard Bioscience Quarterly Data | ||||||||||||||||||||||||||
2015-12 | 2016-03 | 2016-06 | 2016-09 | 2016-12 | 2017-03 | 2017-06 | 2017-09 | 2017-12 | 2018-03 | 2018-06 | 2018-09 | 2018-12 | 2019-03 | 2019-06 | 2019-09 | 2019-12 | 2020-03 | 2020-06 | 2020-09 | 2020-12 | 2021-03 | 2021-06 | 2021-09 | 2021-12 | 2022-03 | |
Forward PE Ratio | 18.25 | 10.04 | 19.92 | 13.61 | 16.05 | 16.26 | 16.45 | 19.72 | 18.87 | 24.39 | 26.74 | 21.88 | 11.43 | 19.61 | 10.53 | 11.99 | 14.27 | 14.43 | 35.46 | 27.17 | 14.79 | 19.65 | 20.96 | 23.98 | 19.57 | 15.06 |
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Harvard Bioscience (NAS:HBIO) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Thank you for viewing the detailed overview of Harvard Bioscience's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
James W Green | director, officer: Chief Executive Officer | 12525 CHADRON AVENUE, HAWTHORNE CA 90250 |
Alan I Edrick | director | 20200 SUNBURST STREET, CHATSWORTH CA 91311 |
Jennifer Cote | officer: Interim CFO | C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746 |
Bertrand Loy | director | C/O ENTEGRIS, INC., 129 CONCORD RD, BILLERICA MA 01821 |
Thomas W Loewald | director | 81 WYMAN STREET, WALTHAM MA 02451 |
John F Kennedy | director | C/O NET PERCEPTIONS INC, 7700 FRANCE AVE. SOUTH, EDINA MN 55435 |
Katherine A. Eade | director | C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746 |
Susan M. Steele | director | C/O HILL INTERNATIONAL, INC., 2005 MARKET ST., 17TH FLOOR, PHILADELPHIA PA 19103 |
Kenneth Fletcher Olson | officer: Chief Operating Officer | C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746 |
Michael A. Rossi | officer: Chief Financial Officer | C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746 |
Yash Singh | officer: Executive Vice President | C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746 |
Jeffrey Duchemin | officer: Chief Executive Officer | 14 EASTLAND TERRACE, HAVERHILL MA 01830 |
Kamalam Unninayar | officer: Chief Financial Officer | C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472 |
Robert E. Gagnon | officer: Chief Financial Officer | C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493 |
George Uveges | director | C/O MFIC CORPORATION, 30 OSSIPEE ROAD, NEWTON MA 02464 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 02-21-2022
By GuruFocusNews GuruFocusNews • 04-21-2022
By sperokesalga sperokesalga • 02-28-2023
By PurpleRose PurpleRose • 07-26-2022
By sperokesalga sperokesalga • 04-18-2023
By GuruFocus Research • 11-07-2023
By Marketwired • 11-06-2023
By Marketwired Marketwired • 04-19-2021
By Marketwired • 09-18-2023
By Marketwired Marketwired • 10-18-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.